Semaglutide: which company produces it, and why it matters

You've seen the name semaglutide, here's the company behind it

Picture this: you've read about semaglutide online, you've seen Wegovy mentioned alongside Ozempic, and someone on a forum said they were the same thing. You want to know who actually makes this medicine and whether that distinction matters before you do anything else. It does.

Novo Nordisk, founded in Denmark in 1923, developed semaglutide and holds the global patents and manufacturing authorisations for it. If you want a fuller picture of the company behind Wegovy and how it operates, that context is worth having before you go further. In the UK, the company markets semaglutide under two brand names: Wegovy, which is licensed specifically for weight management, and Ozempic, which is licensed for type 2 diabetes. The doses differ too, Wegovy's maintenance dose reaches 2.4mg weekly (and now up to 7.2mg with newer approvals), while Ozempic tops out at 1mg or 2mg depending on the indication.

There is no other manufacturer of branded semaglutide authorised in the UK. No generic semaglutide injection has received MHRA approval for weight management. If a seller offers you something described as semaglutide that doesn't come with a Novo Nordisk pen and a valid prescription, that is a serious red flag worth reporting.

The NHS medicines page for semaglutide covers both authorised products clearly and is worth a read before you start any research into treatment options.

Why Ozempic isn't the weight-loss medicine people think it is

This trips up a lot of people. Ozempic and Wegovy both contain semaglutide. Both are made by Novo Nordisk. Both involve a weekly injection. But in the UK, only Wegovy is licensed for weight management. Ozempic's MHRA authorisation covers type 2 diabetes, full stop.

Prescribing Ozempic for weight loss would be off-label, and the MHRA has been clear that GLP-1 medicines are not assessed or approved for cosmetic or quick weight loss. A legitimate prescriber working within UK regulations will prescribe Wegovy for weight management, not Ozempic. If you want to understand how the two compare in more detail, a closer look at the semaglutide options is useful background reading.

It's also worth knowing that Rybelsus (another Novo Nordisk product) is oral semaglutide licensed for type 2 diabetes. It uses 3mg, 7mg and 14mg tablet strengths. The new Wegovy tablet uses a completely different dose ladder: 1.5mg, 4mg, 9mg and 25mg. Same molecule, same manufacturer, different product, different purpose. Don't mix them up.

The quickest check you can do right now: look at the medicine's packaging. A genuine Wegovy pen will carry Novo Nordisk's branding, a batch number, and an expiry date. That takes under a minute and tells you a lot.

What Novo Nordisk's involvement means for UK supply and quality

Medicines licensed in the UK must be manufactured to standards set by the MHRA and Good Manufacturing Practice regulations. Because Novo Nordisk supplies Wegovy through the authorised UK supply chain, every pen has been through those checks before it reaches a pharmacy. That's not a marketing claim, it's a regulatory baseline.

Supply has been patchy since Wegovy's UK relaunch, and Novo Nordisk has published demand forecasts to manage expectations. For patients, this means availability can vary by dose and by month. If you're exploring how to access Wegovy through a registered online pharmacy, understanding that supply comes from one manufacturer helps explain why price and availability track each other the way they do. For broader context on cost, the weight-loss treatment overview sets out what's involved in private prescribing.

A pharmacy dispensing genuine Wegovy will source it through the licensed UK supply chain. You can verify any online pharmacy on the GPhC pharmacy register in moments. At nume, our GPhC-registered pharmacy (registration 9012878) sources from Novo Nordisk-authorised UK suppliers only. Every prescription is personally reviewed by a GPhC-registered Independent Prescriber before anything is dispensed.

The oral semaglutide development: what Novo Nordisk announced in 2026

In June 2026 the MHRA approved Novo Nordisk's Wegovy tablet, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. The tablet uses semaglutide co-formulated with an absorption enhancer called SNAC, which allows the medicine to be absorbed through the stomach lining rather than injected. Starting dose is 1.5mg daily, escalating to a 25mg maintenance dose over several months.

For people who find the idea of injections uncomfortable, this is a meaningful development. The full picture on semaglutide in its different forms covers how this sits alongside the injection options. Phase 3 trial data reported an average weight reduction of around 13.6% over 64 weeks versus placebo; among participants who stayed fully adherent to treatment, the figure was approximately 16.6%.

The tablet is not available on the NHS yet, a NICE appraisal would need to happen first. For now, it requires a private prescription following clinical assessment, and if you are also taking a corticosteroid it is worth reading about whether Wegovy can be taken alongside prednisone before starting. Our clinical team can talk you through which semaglutide formulation, if any, is right for your situation. If you're ready to find out, speak to our prescribers through a free consultation.